Macrogen, Inc. Certified as NimbleGen Array Service Provider for Korea
CGH is an important tool that allows the detection of chromosomal abnormalities, copy number variations, and specific breakpoints at much higher resolution over conventional methods. The genomewide and disease associated region focused research that this technology provides on these types of chromosomal phenomenon has the potential to bring significant advances into the development of personalized healthcare options in the future.
"Macrogen is a leading service provider for CNV analysis based on several significant studies completed including the KCDC project targeting Koreanspecific CNVs as well as the world's first highdefinition Asian CNV map." said Dr. Hyungtae Kim, CEO of Macrogen. "I believe that Roche NimbleGen's CGH/CNV microarrays allow Macrogen to remain at the cuttingedge with the latest technologies for CNV studies to provide our customers with a leading microarray service."
"Roche NimbleGen is extremely pleased to welcome Macrogen as our first certified service provider in Korea for the CGH/CNV application. We look to build on our recent KCDC collaboration with Macrogen, which used our high resolution CNV arrays, to strengthen our global position in the field of copy number variation detection" said Dr. Frank Pitzer, CEO of Roche NimbleGen, Inc.
For more information about Roche NimbleGen, please visit www.nimblegen.com
Macrogen, Inc., Seoul Korea, a world leading service provider in the highquality gene analysis, has enjoyed stable and steady growth since 1997 and gained worldwide recognition as a bioengineering company offering comprehensive services in genetic information analysis. Knowing that the 21st century medical revolution requires new genomicbased tools, the company has dedicated itself to providing the fundamental research and development tools such as bioinformatics infrastructure for genetic information analysis and functional genomics. The company offers DNA sequencing, next generation sequencing, microarray service and analysis, and genetically engineered mice services. In addition, Macrogen has been actively expanding its business scope into molecular diagnostics and personal genomics. With a global presence, Macrogen operates through its subsidiaries in Rockville, MD in the U.S., in The Netherlands in Europe, and in Tokyo, Japan. Macrogen is listed on the Korea Securities Dealers Automated Quotation (ticker symbol: A038290). For more information, visit www.macrogen.com.
Über Roche Diagnostics GmbH
Headquartered in Basel, Switzerland, Roche is a leader in researchfocused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in invitro diagnostics, tissuebased cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80'000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.